Is Clover Health Finally Turning the Corner?
After years of burning cash and testing investor patience, Clover Health just posted results that bulls have been waiting for. But with medical costs creeping up and the stock already priced for perfection, the real question is whether this milestone…
Clover Health (NASDAQ:CLOV) has spent years as a speculative bet on a technology-led Medicare Advantage model. The Q1 2026 report, released May 6, 2026, offered the first quarter that lets bulls make a numbers-based case rather than a narrative one.
The Bull Case: A Profitability Inflection
The Nashville-based insurer swung to GAAP net income of $27.33 million, compared with a $1.27 million loss a year earlier, on revenue of $749.19 million, up 62.05% year over year and topping the $714.89 million estimate by 4.80%. Operating cash flow reached $107.89 million, a 762.22% jump, and adjusted EBITDA of $40 million rose 56% year over year.
Membership scale is the engine. Average Medicare Advantage membership grew 51.6% to 154,607, while adjusted SG&A improved 210 basis points to 15.9% of revenue. CEO Andrew Toy told investors: “Entering 2026, our first quarter results demonstrate how market-leading growth, GAAP net income profitability and full risk can scale together in Medicare Advantage.” He added that “over 1/3 of our members received Clover Assistant-powered care,” with Counterpart Health extending the platform to external payors and providers.
Management reaffirmed FY2026 guidance for revenue of $2.81 billion to $2.92 billion, adjusted EBITDA of $50 million to $70 million, and GAAP net income of $0 million to $20 million, which would mark the company’s first full fiscal year of GAAP profitability.
The Bear Case: Cost Trends and Regulatory Overhang
The Insurance Benefit Expense Ratio rose 40 basis points to 86.5%, with net medical claims growing 65.8% versus premium growth of 62.9%. Unpaid claims climbed to $260.4 million from $153.3 million at year-end 2025. The reported EPS of $0.05 missed the $0.07 estimate by 28.57%.
Valuation leaves little cushion. Trailing metrics show a forward P/E of 82, price-to-book of 6.5, and a beta of 2.42. Volatility is extreme: shares are up 77.5% year to date to $4.17, but down 20.4% over the past month. The net insider trading direction is selling, and Toy himself cautioned that outpatient utilization “continues to be elevated.” CMS rate policy, Star Ratings, and risk-model changes remain persistent overhangs.
Sentiment and the Verdict
Wall Street coverage is thin. The mean price target is $4.58, and the composite prediction sentiment score is a neutral 49.34.
Clover is clearly turning a corner operationally: a real GAAP profit, expanding membership, and Clover Assistant reaching a meaningful share of members. Yet with medical cost trends creeping higher, reserves building, and the stock priced at about 82 times forward earnings, the corner has already been partly priced in. The turnaround is credible; the margin of safety is slim. Investors should monitor Q2 2026 results and any updated guidance for confirmation.
Contact [email protected] for any questions or corrections.
Trey has been an editor and author at 24/7 Wall St. for more than a decade, where he has published thousands of articles analyzing corporate earnings, dividend stocks, short interest, insider buying, private equity, and market trends. His comprehensive coverage spans the full spectrum of financial markets, from blue-chip stalwarts to emerging growth companies.
Beyond 24/7 Wall St., Trey has created and edited financial content for Benzinga and AOL's BloggingStocks, contributing additional hundreds of articles to the investment community. He previously oversaw the 24/7 Climate Insights site, managing editorial operations and content strategy, and currently oversees and creates content for My Investing News.
Trey's editorial expertise extends across multiple publishing environments. He served as production editor at Dearborn Financial Publishing and development editor at Kaplan, where he helped shape financial education materials. Earlier in his career, he worked as a writer-producer at SVE. His freelance editing portfolio includes work for prestigious clients such as Sage Publications, Rand McNally, the Institute for Supply Management, the American Library Association, Eggplant Literary Productions, and Spiegel.
Outside of financial journalism, Trey writes fiction and has been an active member of the writing community for years, overseeing a long-running critique group and moderating workshop sessions at regional conventions. He lives with his family in an old house in the Midwest.
